Skip to main content

NYSE:CVS - CVS Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $91.69
  • Forecasted Upside: 7.73 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$85.11
▲ +1.41 (1.68%)
1 month | 3 months | 12 months
Get New CVS Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$91.69
▲ +7.73% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for CVS Health in the last 3 months. The average price target is $91.69, with a high forecast of $101.00 and a low forecast of $76.00. The average price target represents a 7.73% upside from the last price of $85.11.

Buy

The current consensus among 12 contributing investment analysts is to buy stock in CVS Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 17 buy ratings
  • 8 hold ratings
  • 0 sell ratings
11/15/2019
  • 2 strong buy ratings
  • 17 buy ratings
  • 7 hold ratings
  • 0 sell ratings
2/13/2020
  • 2 strong buy ratings
  • 15 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/13/2020
  • 2 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/11/2020
  • 2 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/9/2020
  • 1 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/7/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/8/2021
  • 1 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/8/2021

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021Credit Suisse GroupBoost Price TargetOutperform$91.00 ➝ $100.00Low
i
5/6/2021BMO Capital MarketsBoost Price TargetMarket Perform$82.00 ➝ $90.00Low
i
5/5/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$83.00 ➝ $98.00Low
i
5/5/2021CitigroupBoost Price Target$83.00 ➝ $98.00Medium
i
5/5/2021Jefferies Financial GroupBoost Price TargetBuy$90.00 ➝ $95.00Medium
i
5/5/2021Raymond JamesBoost Price TargetStrong-Buy$90.00 ➝ $95.00High
i
5/5/2021Royal Bank of CanadaBoost Price TargetOutperform$80.00 ➝ $91.00High
i
4/20/2021Morgan StanleyBoost Price TargetOverweight$86.00 ➝ $92.00Low
i
4/20/2021Truist SecuritiesBoost Price TargetBuy$80.00 ➝ $88.00Low
i
4/14/2021TruistBoost Price Target$80.00 ➝ $88.00Medium
i
4/14/2021Truist SecuritiesBoost Price TargetBuy$80.00 ➝ $88.00Low
i
4/14/2021Morgan StanleyBoost Price TargetOverweight$86.00 ➝ $92.00Medium
i
3/23/2021GuggenheimReiterated RatingBuy ➝ NeutralMedium
i
3/17/2021GuggenheimDowngradeBuy ➝ NeutralLow
i
1/8/2021Jefferies Financial GroupUpgradeHold ➝ Buy$90.00Low
i
12/14/2020SVB LeerinkBoost Price TargetMarket Perform$73.00 ➝ $80.00High
i
Rating by D. Ha at SVB Leerink LLC
11/11/2020Piper SandlerBoost Price TargetOverweight$72.00 ➝ $76.00Low
i
11/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by S. Halper at Cantor Fitzgerald
11/9/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$104.00 ➝ $101.00High
i
9/17/2020Piper SandlerInitiated CoverageOverweight$72.00 ➝ $72.00Medium
i
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$75.00 ➝ $90.00Medium
i
Rating by A.J. Rice at Credit Suisse Group AG
8/6/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$109.00 ➝ $104.00Low
i
8/6/2020SVB LeerinkBoost Price TargetMarket Perform$72.00 ➝ $73.00Low
i
Rating by D. Ha at SVB Leerink LLC
7/9/2020Royal Bank of CanadaReiterated RatingBuyLow
i
7/1/2020SVB LeerinkInitiated CoverageMarket Perform$72.00Low
i
Rating by S. Davis at SVB Leerink LLC
5/14/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$75.00Low
i
Rating by Erin Wright at Credit Suisse Group AG
5/8/2020Credit Suisse GroupReiterated RatingHoldLow
i
Rating by Erin Wright at Credit Suisse Group AG
5/7/2020Robert W. BairdBoost Price TargetNeutral$62.00 ➝ $66.00Low
i
5/7/2020UBS GroupLower Price TargetBuy$85.00 ➝ $79.00Low
i
5/7/2020CitigroupLower Price TargetBuy$86.00 ➝ $75.00Low
i
5/7/2020Morgan StanleyBoost Price TargetOverweight$71.00 ➝ $77.00Low
i
5/6/2020Royal Bank of CanadaReiterated RatingBuy$77.00High
i
5/6/2020OppenheimerReiterated RatingHoldHigh
i
Rating by Michael Wiederhorn at Oppenheimer Holdings Inc.
5/4/2020JPMorgan Chase & Co.Lower Price TargetOverweight$97.00 ➝ $94.00Low
i
4/24/2020Tigress FinancialReiterated RatingBuyMedium
i
Rating by Ivan Feinseth at Tigress Financial
4/13/2020Morgan StanleyBoost Price TargetOverweight$70.00 ➝ $71.00Low
i
4/13/2020SunTrust BanksLower Price TargetBuy$90.00 ➝ $80.00Medium
i
4/12/2020Royal Bank of CanadaReiterated RatingBuy$77.00High
i
3/27/2020Morgan StanleyLower Price TargetOverweight$88.00 ➝ $70.00Medium
i
3/27/2020Robert W. BairdLower Price TargetNeutral$73.00 ➝ $62.00Medium
i
3/25/2020Royal Bank of CanadaLower Price Target$85.00 ➝ $81.00Medium
i
Rating by Anton Hie at Royal Bank of Canada
3/19/2020Credit Suisse GroupReiterated RatingHold$75.00Medium
i
Rating by Erin Wright at Credit Suisse Group AG
2/18/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$97.00 ➝ $109.00Low
i
2/14/2020CitigroupBoost Price TargetBuy$83.00 ➝ $86.00Medium
i
2/13/2020Robert W. BairdBoost Price TargetNeutral$70.00 ➝ $73.00Medium
i
2/13/2020UBS GroupBoost Price TargetBuy$78.00 ➝ $85.00Medium
i
2/13/2020Cantor FitzgeraldBoost Price TargetOverweight$85.00 ➝ $90.00Medium
i
2/12/2020OppenheimerInitiated CoverageHoldMedium
i
Rating by Michael Wiederhorn at Oppenheimer Holdings Inc.
2/12/2020CfraBoost Price TargetStrong-Buy$85.00 ➝ $86.00Medium
i
12/19/2019JPMorgan Chase & Co.Boost Price TargetOverweight$88.00 ➝ $97.00Low
i
12/4/2019Raymond JamesReiterated RatingStrong-Buy$80.00 ➝ $90.00Low
i
11/8/2019MizuhoBoost Price TargetBuy$71.00 ➝ $82.00Low
i
Rating by Ann Hynes at Mizuho
11/7/2019UBS GroupReiterated RatingBuy$78.00 ➝ $78.00Low
i
11/7/2019Raymond JamesBoost Price TargetStrong-Buy$75.00 ➝ $80.00Low
i
11/7/2019SunTrust BanksBoost Price TargetBuy$85.00Low
i
11/7/2019CitigroupBoost Price TargetBuy$72.00 ➝ $83.00Low
i
10/21/2019CowenSet Price TargetBuy$76.00Low
i
Rating by Charles Rhyee at Cowen Inc
9/27/2019Royal Bank of CanadaInitiated CoverageOutperform$85.00Low
i
9/26/2019Morgan StanleyBoost Price TargetOverweight$74.00 ➝ $77.00Medium
i
Rating by Ricky Goldwasser at Morgan Stanley
9/12/2019Bank of AmericaBoost Price TargetBuy$72.00 ➝ $75.00Low
i
9/12/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$91.00Medium
i
8/27/2019CowenReiterated RatingOutperform$69.00 ➝ $76.00Medium
i
8/11/2019Morgan StanleyReiterated RatingBuy$74.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
8/8/2019CitigroupBoost Price TargetBuy$68.00 ➝ $72.00Medium
i
Rating by Ralph Giacobbe at Citigroup Inc.
8/7/2019Evercore ISISet Price TargetBuy$63.00Low
i
Rating by Ross Muken at Evercore ISI
6/5/2019MizuhoSet Price TargetBuy$71.00Medium
i
Rating by Ann Hynes at Mizuho
6/5/2019Standpoint ResearchUpgradeHold ➝ BuyHigh
i
5/3/2019BMO Capital MarketsSet Price TargetHold$63.00Low
i
Rating by Matthew Borsch at BMO Capital Markets
5/2/2019CitigroupSet Price TargetBuy$74.00Low
i
Rating by Ralph Giacobbe at Citigroup Inc.
5/2/2019UBS GroupLower Price TargetSell ➝ Sell$74.00 ➝ $67.00Low
i
5/1/2019Cantor FitzgeraldReiterated RatingBuy$80.00Low
i
Rating by S. Halper at Cantor Fitzgerald
4/29/2019Morgan StanleyLower Price TargetOverweight ➝ Overweight$92.00 ➝ $74.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
4/29/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$73.00 ➝ $61.00Medium
i
4/21/2019Cantor FitzgeraldReiterated RatingBuy$80.00Low
i
Rating by S. Halper at Cantor Fitzgerald
4/18/2019Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$90.00 ➝ $75.00Low
i
4/18/2019GuggenheimInitiated CoverageBuy ➝ Buy$90.00 ➝ $75.00Low
i
4/15/2019CIBCReiterated RatingOutperform ➝ Market PerformLow
i
4/15/2019OppenheimerDowngradeOutperform ➝ Market PerformLow
i
4/11/2019BarclaysSet Price TargetBuy$73.00High
i
Rating by Steven Valiquette at Barclays PLC
4/10/2019BMO Capital MarketsInitiated CoverageOutperform$58.00Medium
i
4/10/2019SunTrust BanksLower Price Target$85.00 ➝ $65.00Low
i
4/10/2019Bank of AmericaReiterated RatingBuy$82.00 ➝ $74.00Low
i
3/12/2019Sanford C. BernsteinInitiated CoverageOutperform ➝ Outperform$76.00High
i
3/6/2019CitigroupLower Price TargetBuy ➝ Buy$94.00 ➝ $68.00Medium
i
2/25/2019ArgusLower Price TargetBuy ➝ Positive$100.00 ➝ $80.00Low
i
2/22/2019Morgan StanleySet Price TargetBuy$92.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
2/21/2019SunTrust BanksLower Price TargetBuy$85.00Medium
i
2/21/2019UBS GroupLower Price TargetBuy ➝ Buy$75.00 ➝ $74.00High
i
2/21/2019Loop CapitalLower Price TargetIn-Line ➝ Hold$68.00High
i
Rating by Andrew Wolf at Loop Capital
2/21/2019JPMorgan Chase & Co.Reiterated RatingOverweight$91.00High
i
2/21/2019Cantor FitzgeraldReiterated RatingOverweight$80.00High
i
Rating by S. Halper at Cantor Fitzgerald
2/20/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$104.00 ➝ $68.00High
i
1/17/2019UBS GroupInitiated CoverageBuy ➝ Buy$75.00Low
i
1/3/2019Cantor FitzgeraldReiterated RatingBuy$96.00Low
i
Rating by S. Halper at Cantor Fitzgerald
1/3/2019Bank of AmericaReiterated RatingBuy$92.00Low
i
12/18/2018BarclaysInitiated CoverageOverweight ➝ Overweight$91.00Medium
i
12/11/2018SVB LeerinkInitiated CoverageOutperformMedium
i
Rating by David Larsen at SVB Leerink LLC
12/2/2018Cantor FitzgeraldInitiated CoverageOverweight$96.00 ➝ $77.84Low
i
Rating by S. Halper at Cantor Fitzgerald
11/29/2018The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$87.00Low
i
11/28/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$89.00Low
i
11/28/2018Loop CapitalSet Price TargetHold$80.00High
i
Rating by Andrew Wolf at Loop Capital
11/27/2018Wells Fargo & CompanyBoost Price TargetOutperform$98.00 ➝ $104.00Medium
i
11/26/2018Cantor FitzgeraldInitiated CoverageOverweight$96.00High
i
Rating by S. Halper at Cantor Fitzgerald
11/13/2018ArgusBoost Price TargetBuy$100.00Low
i
11/9/2018Loop CapitalSet Price TargetHold$70.00 ➝ $80.00N/A
i
Rating by Andrew Wolf at Loop Capital
11/8/2018SVB LeerinkBoost Price TargetOutperform ➝ Positive$85.00 ➝ $95.00Medium
i
Rating by David Larsen at SVB Leerink LLC
11/7/2018Morgan StanleySet Price TargetBuy$80.00 ➝ $100.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
11/7/2018Royal Bank of CanadaSet Price TargetBuy$100.00Medium
i
Rating by George Hill at Royal Bank of Canada
10/26/2018Tigress FinancialReiterated RatingBuyLow
i
10/25/2018Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
i
10/23/2018Royal Bank of CanadaSet Price TargetBuy$99.00Low
i
Rating by George Hill at Royal Bank of Canada
9/18/2018Royal Bank of CanadaBoost Price TargetOutperform$101.00Medium
i
Rating by George Hill at Royal Bank of Canada
9/17/2018Bank of AmericaBoost Price TargetBuy$86.00 ➝ $90.00Medium
i
8/9/2018SVB LeerinkSet Price TargetOutperform$85.00 ➝ $80.00Low
i
Rating by David Larsen at SVB Leerink LLC
8/8/2018Royal Bank of CanadaReiterated RatingPositive ➝ Buy$90.00Low
i
Rating by George Hill at Royal Bank of Canada
7/9/2018CitigroupReiterated RatingNeutral ➝ Buy$81.00Low
i
Rating by Alvin Concepcion at Citigroup Inc.
7/3/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$88.00 ➝ $80.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
6/30/2018MizuhoReiterated RatingBuyLow
i
Rating by Ann Hynes at Mizuho
6/29/2018Royal Bank of CanadaLower Price TargetOutperform$84.00Medium
i
Rating by George Hill at Royal Bank of Canada
6/13/2018MizuhoSet Price TargetBuy$95.00High
i
Rating by Ann Hynes at Mizuho
5/7/2018Loop CapitalSet Price TargetHold$68.00Medium
i
Rating by Andrew Wolf at Loop Capital
4/11/2018Bank of AmericaLower Price TargetBuy ➝ Buy$91.00 ➝ $88.00Low
i
Rating by Michael Cherny at Bank of America Co.
4/10/2018SVB LeerinkSet Price TargetBuy$85.00Low
i
Rating by David Larsen at SVB Leerink LLC
2/27/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$91.00Low
i
2/13/2018CitigroupSet Price TargetNeutral ➝ Neutral$80.00 ➝ $77.00Low
i
Rating by Alvin Concepcion at Citigroup Inc.
2/9/2018SVB LeerinkSet Price TargetOutperform ➝ Buy$90.00 ➝ $85.00Low
i
Rating by David Larsen at SVB Leerink LLC
2/9/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$85.00 ➝ $80.00Low
i
Rating by Eric Coldwell at Robert W. Baird
2/9/2018Needham & Company LLCSet Price TargetStrong-Buy ➝ Buy$100.00 ➝ $98.00Medium
i
Rating by Kevin Caliendo at Needham & Company LLC
2/8/2018Royal Bank of CanadaSet Price TargetBuy$89.00Medium
i
Rating by George Hill at Royal Bank of Canada
1/30/2018Needham & Company LLCUpgradeBuy ➝ Strong-Buy$88.00 ➝ $100.00High
i
Rating by Kevin Caliendo at Needham & Company LLC
1/24/2018MizuhoSet Price TargetBuy$95.00Low
i
Rating by Ann Hynes at Mizuho
1/18/2018CowenReiterated RatingOutperform$81.00 ➝ $99.00Low
i
Rating by Charles Rhyee at Cowen Inc
1/8/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$82.00 ➝ $90.00Low
i
Rating by David Larsen at SVB Leerink LLC
1/5/2018SunTrust BanksBoost Price TargetBuy$90.00High
i
Rating by David S Macdonald at SunTrust Banks, Inc.
1/5/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$88.00High
i
1/4/2018Raymond JamesUpgradeOutperform ➝ Strong-Buy$90.00High
i
1/4/2018UBS GroupUpgradeOutperform ➝ Strong-BuyHigh
i
1/2/2018Needham & Company LLCBoost Price TargetBuy$85.00 ➝ $88.00Medium
i
Rating by Kevin Caliendo at Needham & Company LLC
12/26/2017Tigress FinancialReiterated RatingBuyLow
i
12/5/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ HoldMedium
i
12/4/2017Raymond JamesReiterated RatingBuyLow
i
12/4/2017Royal Bank of CanadaSet Price TargetBuy$95.00Low
i
Rating by George Hill at Royal Bank of Canada
12/4/2017Robert W. BairdSet Price TargetHold$77.00Medium
i
Rating by Eric Coldwell at Robert W. Baird
12/4/2017Jefferies Financial GroupSet Price TargetHold$76.00Medium
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
12/4/2017Loop CapitalSet Price TargetHold$73.00Medium
i
Rating by Andrew Wolf at Loop Capital
12/4/2017CitigroupSet Price TargetHold$76.00Medium
i
Rating by Alvin Concepcion at Citigroup Inc.
12/4/2017SVB LeerinkSet Price TargetBuy$85.00High
i
Rating by David Larsen at SVB Leerink LLC
12/4/2017Needham & Company LLCBoost Price TargetBuy$79.00 ➝ $85.00High
i
Rating by Kevin Caliendo at Needham & Company LLC
12/4/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$69.00 ➝ $90.00High
i
11/10/2017Needham & Company LLCUpgradeHold ➝ Buy$69.02 ➝ $79.00N/A
i
Rating by Kevin Caliendo at Needham & Company LLC
11/7/2017Loop CapitalLower Price TargetHold$83.00 ➝ $73.00N/A
i
Rating by Andrew Wolf at Loop Capital
11/7/2017Jefferies Financial GroupLower Price TargetHold$86.00 ➝ $76.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
11/7/2017SVB LeerinkReiterated RatingHold ➝ Outperform$90.00 ➝ $85.00N/A
i
Rating by David Larsen at SVB Leerink LLC
11/3/2017CitigroupLower Price TargetNeutral$87.00 ➝ $74.00N/A
i
10/29/2017CowenSet Price TargetBuy$86.00N/A
i
Rating by Charles Rhyee at Cowen Inc
10/27/2017Loop CapitalReiterated RatingHoldN/A
i
Rating by Andrew Wolf at Loop Capital
10/27/2017Robert W. BairdReiterated RatingHold$77.00N/A
i
10/24/2017MizuhoSet Price TargetBuy$90.00N/A
i
10/18/2017Jefferies Financial GroupSet Price TargetHold$86.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
10/12/2017SunTrust BanksSet Price TargetBuy$85.00N/A
i
10/12/2017Needham & Company LLCReiterated RatingHoldN/A
i
Rating by Kevin Caliendo at Needham & Company LLC
10/9/2017OppenheimerReiterated RatingBuy$95.00N/A
i
9/19/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$95.00Low
i
9/15/2017Jefferies Financial GroupBoost Price TargetHold ➝ Hold$82.00 ➝ $86.00Medium
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
9/10/2017Needham & Company LLCReiterated RatingHoldLow
i
Rating by Kevin Caliendo at Needham & Company LLC
8/24/2017Loop CapitalInitiated CoverageHold ➝ Hold$83.00Low
i
8/17/2017CitigroupLower Price TargetNeutral$88.00 ➝ $87.00Low
i
8/14/2017Robert W. BairdReiterated RatingOutperform$90.00Low
i
8/14/2017Wolfe ResearchDowngradeOutperform ➝ Market Perform$89.00 ➝ $82.00Low
i
7/14/2017Jefferies Financial GroupReiterated RatingHold$82.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
7/3/2017GuggenheimReiterated RatingBuyLow
i
6/27/2017Needham & Company LLCInitiated CoverageHold ➝ HoldLow
i
6/27/2017SVB LeerinkSet Price TargetBuy$90.00N/A
i
Rating by David Larsen at SVB Leerink LLC
6/13/2017CowenReiterated RatingOutperform$86.00Low
i
6/9/2017Jefferies Financial GroupReiterated RatingHold$82.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
5/3/2017Evercore ISIReiterated RatingOutperform$87.00 ➝ $88.00Low
i
4/27/2017Tigress FinancialInitiated CoverageBuy ➝ BuyLow
i
4/4/2017UBS GroupReiterated RatingBuy$89.00 ➝ $88.00N/A
i
Rating by Michael Cherny at UBS Group AG
4/1/2017Jefferies Financial GroupSet Price TargetHold$82.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
3/28/2017GuggenheimReiterated RatingBuy$90.00Low
i
3/18/2017SVB LeerinkSet Price TargetBuy$90.00Low
i
Rating by David Larsen at SVB Leerink LLC
2/28/2017Bank of AmericaReiterated RatingBuy$106.67N/A
i
2/16/2017UBS GroupReiterated RatingBuy$88.50 ➝ $89.00N/A
i
Rating by Michael Cherny at UBS Group AG
2/11/2017SVB LeerinkSet Price TargetBuy$90.00N/A
i
Rating by David Larsen at SVB Leerink LLC
2/10/2017UBS GroupSet Price TargetBuy$89.00N/A
i
Rating by Michael Cherny at UBS Group AG
2/9/2017Evercore ISILower Price TargetBuy$91.50 ➝ $84.00N/A
i
2/8/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$88.00N/A
i
2/6/2017Atlantic SecuritiesDowngradeOverweight ➝ Neutral$84.00N/A
i
2/6/2017GuggenheimReiterated RatingBuy$90.00N/A
i
2/4/2017UBS GroupSet Price TargetBuy$89.00N/A
i
Rating by Michael Cherny at UBS Group AG
2/2/2017Robert W. BairdDowngradeOutperform ➝ Neutral$86.00 ➝ $77.00N/A
i
12/28/2016GuggenheimReiterated RatingBuy$90.00N/A
i
12/19/2016Credit Suisse GroupReiterated RatingBuyN/A
i
12/18/2016OppenheimerSet Price TargetBuy$88.00N/A
i
Rating by Mohan Naidu at Oppenheimer Holdings Inc.
12/13/2016GuggenheimReiterated RatingBuy$90.00N/A
i
12/12/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$122.00 ➝ $82.00N/A
i
11/10/2016ArgusReiterated RatingBuy$120.00 ➝ $85.00N/A
i
11/9/2016BarclaysReiterated RatingBuy$85.00N/A
i
11/9/2016SVB LeerinkReiterated RatingBuy$105.00N/A
i
Rating by David Larsen at SVB Leerink LLC
11/9/2016MizuhoBoost Price TargetBuy$90.00 ➝ $111.00N/A
i
Rating by Ann Hynes at Mizuho
11/8/2016GuggenheimReiterated RatingBuy$115.00 ➝ $90.00N/A
i
10/18/2016Deutsche Bank AktiengesellschaftReiterated RatingHold$108.00 ➝ $99.00N/A
i
Rating by George Hill at Deutsche Bank Aktiengesellschaft
10/5/2016UBS GroupInitiated CoverageBuy$107.00N/A
i
10/4/2016Credit Suisse GroupReiterated RatingOutperform$115.00 ➝ $110.00N/A
i
Rating by Robert Willoughby at Credit Suisse Group AG
10/3/2016Robert W. BairdLower Price TargetOutperform$114.00 ➝ $104.00N/A
i
10/2/2016SVB LeerinkReiterated RatingOutperform$110.00 ➝ $105.00N/A
i
Rating by David Larsen at SVB Leerink LLC
9/30/2016MizuhoReiterated RatingBuy$111.00N/A
i
Rating by Ann Hynes at Mizuho
9/20/2016Credit Suisse GroupReiterated RatingBuy$115.00N/A
i
Rating by Robert Willoughby at Credit Suisse Group AG
9/12/2016Morgan StanleyReiterated RatingHold$104.00N/A
i
Rating by Ricky Goldwasser at Morgan Stanley
8/8/2016CitigroupLower Price TargetNeutral$115.00 ➝ $108.00N/A
i
8/4/2016ArgusReiterated RatingBuy$120.00N/A
i
8/4/2016MizuhoBoost Price TargetBuy$108.00 ➝ $111.00N/A
i
Rating by Ann Hynes at Mizuho
8/3/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by David Larsen at SVB Leerink LLC
8/3/2016Morgan StanleyReiterated RatingHold$104.00N/A
i
Rating by Ricky Goldwasser at Morgan Stanley
8/3/2016Deutsche Bank AktiengesellschaftBoost Price TargetHold$99.00 ➝ $108.00N/A
i
Rating by George Hill at Deutsche Bank Aktiengesellschaft
8/3/2016(FBRC)Reiterated RatingOutperform$120.00N/A
i
Rating by Steven Halper at (FBRC)
7/4/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Mark Wiltamuth at Jefferies Financial Group Inc.
6/23/2016MizuhoReiterated RatingBuy$117.00 ➝ $108.00N/A
i
Rating by Ann Hynes at Mizuho
6/22/2016Deutsche Bank AktiengesellschaftBoost Price TargetHold$99.00 ➝ $105.00N/A
i
Rating by George Hill at Deutsche Bank Aktiengesellschaft
6/20/2016Morgan StanleyDowngradeOverweight ➝ Equal Weight$111.00 ➝ $104.00N/A
i
Rating by Ricky Goldwasser at Morgan Stanley
6/10/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by David Larsen at SVB Leerink LLC
6/5/2016Credit Suisse GroupReiterated RatingBuy$115.00N/A
i
5/14/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Steven Halper at (FBRC)
5/12/2016Jefferies Financial GroupBoost Price TargetBuy$110.00 ➝ $122.00N/A
i
5/9/2016CitigroupBoost Price TargetNeutral$105.00 ➝ $115.00N/A
i
Rating by Alvin Concepcion at Citigroup Inc.
(Data available from 5/9/2016 forward)
CVS Health logo
CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. Its Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. As of December 31, 2020, it operated approximately 9,900 retail locations and 1,100 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Read More

Today's Range

Now: $85.11
$83.71
$85.35

50 Day Range

MA: $75.53
$71.90
$83.70

52 Week Range

Now: $85.11
$55.36
$85.35

Volume

8,206,262 shs

Average Volume

6,982,176 shs

Market Capitalization

$112.05 billion

P/E Ratio

14.07

Dividend Yield

2.39%

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of CVS Health?

The following Wall Street analysts have issued stock ratings on CVS Health in the last twelve months: BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, Raymond James, Royal Bank of Canada, SVB Leerink LLC, Truist, and Truist Securities.
View the latest analyst ratings for CVS.

What is the current price target for CVS Health?

13 Wall Street analysts have set twelve-month price targets for CVS Health in the last year. Their average twelve-month price target is $91.69, suggesting a possible upside of 7.7%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting CVS will reach $101.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $76.00 for CVS Health in the next year.
View the latest price targets for CVS.

What is the current consensus analyst rating for CVS Health?

CVS Health currently has 3 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CVS will outperform the market and that investors should add to their positions of CVS Health.
View the latest ratings for CVS.

What other companies compete with CVS Health?

How do I contact CVS Health's investor relations team?

CVS Health's physical mailing address is ONE CVS DR., WOONSOCKET RI, 02895. The pharmacy operator's listed phone number is 401-765-1500 and its investor relations email address is [email protected] The official website for CVS Health is www.cvshealth.com.